We are live on ! Find out more
AC

Aisling Capital Portfolio holdings

AUM $45.3M
1-Year Est. Return 15.24%
This Fund
S&P 500
This Quarter Est. Return
+44.6%
1 Year Est. Return
-15.24%
3 Year Est. Return
+386.13%
5 Year Est. Return
+981.36%
10 Year Est. Return
–
AUM
$762M
AUM Growth
+$201M
Cap. Flow
-$14.3M
Cap. Flow %
-1.88%
Top 10 Hldgs %
100%
Holding
10
New
–
Increased
–
Reduced
1
Closed
1

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
ASXC
Asensus Surgical, Inc.
ASXC
+$9.81M
2
AGRX
Agile Therapeutics
AGRX
+$3.35M

Sector Composition

Rank Sector Weight
1 Healthcare 85.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LOXO
1
DELISTED
Loxo Oncology, Inc
LOXO
$597M 78.3%
3,438,920
– –
AIMT
2
DELISTED
Aimmune Therapeutics
AIMT
$60.2M 7.91%
2,240,000
– –
VRAY
3
DELISTED
ViewRay, Inc.
VRAY
$51.8M 6.79%
7,480,887
– –
ASXC
4
DELISTED
Asensus Surgical, Inc.
ASXC
$27.9M 3.66%
491,489
-269,230
-35% -$9.81M
ADMA icon
5
ADMA Biologics
ADMA
$2.03B
$16.3M 2.14%
3,608,171
– –
CDTX
6
DELISTED
Cidara Therapeutics
CDTX
$5.31M 0.7%
51,057
– –
CMRX
7
DELISTED
Chimerix, Inc.
CMRX
$2.25M 0.3%
472,943
– –
PTX
8
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
$510K 0.07%
210,000
– –
AGRX
9
DELISTED
Agile Therapeutics
AGRX
– –
-652
Closed -$3.35M

Similar funds

SCPM
Sagard Capital Partners Management New York $46.7M AUM 23.43% 1-Year Est. Return
ZIM
ZPR Investment Management Orange City, Florida $46.8M AUM 2.45% 1-Year Est. Return
ACP
Aquiline Capital Partners New York $46.9M AUM 5.65% 1-Year Est. Return
INL
IPC/NYCG LLC New York $43.3M AUM 61.41% 1-Year Est. Return
CP
Clover Partners Dallas, Texas $43.1M AUM 4.09% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return
JCM
Julex Capital Management Wellesley, Massachusetts $42.4M AUM 9.78% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return

Aisling Capital's Q2 2018 Portfolio in Review

As of Q2 2018, Aisling Capital held 10 positions worth $762M, up 36% from $561M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Aisling Capital's Q2 2018 filing shows 1 reduced and 1 closed positions. The largest sale was Asensus Surgical, Inc., an estimated $9.81M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 78% a quarter earlier.

  • Aisling Capital's biggest Q2 2018 reduction was Asensus Surgical, Inc., cutting an estimated $9.81M.
  • Aisling Capital fully exited Agile Therapeutics in Q2 2018, selling an estimated $3.35M.
  • Aisling Capital's ten largest holdings make up 100% of its $762M portfolio in Q2 2018.
  • Aisling Capital opened 0 new positions and closed 1 in Q2 2018.
  • Aisling Capital's portfolio value rose 36% quarter-over-quarter to $762M.

Based on Aisling Capital's 13F filing for Q2 2018, filed 13 Aug 2018.